

PRESS RELEASE FROM *GENETICS IN MEDICINE*
(<http://www.nature.com/gim>)

This press release is copyrighted to the journal *Genetics in Medicine*.
Its use is granted only for journalists and news media receiving it directly from the Nature
Publishing Group.

*** PLEASE DO NOT REDISTRIBUTE THIS DOCUMENT ***

EMBARGO:

1700 London time (BST) / 1200 US Eastern Time Thursday 7 August 2014
0100 Japanese time / 0200 Australian Eastern Time Friday 8 August 2014

Wire services' stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.

Solely for the purpose of soliciting informed comment on this paper, you may show it to independent specialists - but you must ensure in advance that they understand and accept the embargo conditions.

A PDF of the paper mentioned on this release can be found in the Academic Journals section of <http://press.nature.com>. Press contacts for the journals are listed at the end of this release.

Warning: This document, and the papers to which it refers, may contain sensitive or confidential information not yet disclosed to the public. Using, sharing or disclosing this information to others in connection with securities dealing or trading may be a violation of insider trading under the laws of several countries, including, but not limited to, the UK Financial Services and Markets Act 2000 and the US Securities Exchange Act of 1934, each of which may be subject to penalties and imprisonment.

PICTURES: While we are happy for images from *Genetics in Medicine* to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at press@nature.com, citing the specific example.

PLEASE CITE *GENETICS IN MEDICINE* AND THE *GENETICS IN MEDICINE* WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO <http://www.nature.com/gim/>

[Reliability of non-invasive prenatal testing questioned](#)

DOI: 10.1038/GIM.2014.92

The use of non-invasive prenatal testing (NIPT) to identify chromosomal abnormalities may produce a higher rate of false positives than previously thought, according to a study published in *Genetics in Medicine*. The authors suggest that NIPT results should be interpreted with caution, and should not be considered as providing a definitive fetal diagnosis.

During pregnancy, maternal blood contains small fragments of cell-free, fetal DNA derived from the placenta. This provides a non-invasive method for testing for chromosomal abnormalities in the fetus by comparing the relative amounts of cell-free DNA from each chromosome; if the levels of DNA belonging to a specific chromosome are abnormally high, for example, it suggests the presence of an extra chromosome. Previous studies have reported conflicting results on the specificity and sensitivity of

these tests for conditions such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome).

Jia-Chi Wang and colleagues analyzed 109 cases of NIPT-positive results, comparing these findings with those attained from definitive methods, such as karyotyping, a test that examines the number and structural integrity of chromosomes. They found that the rates for which results from NIPT were confirmed in the fetus ranged from 93% (38 out of 41 cases) for trisomy 21, to 38% (6 out of 16 cases) for sex chromosome abnormalities. Combining these data with the results from related studies, Wang and colleagues calculated that the positive predictive value of NIPT, which takes into account the population incidence of the specific disorders, is: 94.4% for trisomy 21, 59.5% for trisomy 18, 44.4% for trisomy 13, and 37.9% for sex chromosome abnormalities. This suggests that if a NIPT result is positive for trisomy 18, for example, the likelihood that the fetus actually has the disorder is less than 60%.

The authors note that the findings highlight the limitations of NIPT. They suggest that further studies are needed to improve the accuracy of these tests' predictive ability, and to understand the biological or technical source of the test's limitations.

CONTACT

Jia-Chi Wang (Quest Diagnostics, San Juan Capistrano, CA, USA)

Tel: +1 949 728 4336; E-mail: jia-chi.j.wang@questdiagnostics.com

Editorial contact from *Genetics in Medicine*:

Jan Higgins (Managing Editor, Genetics in Medicine, Bethesda, MD, USA)

E-mail: gim@acmg.net

Media contact from the American College of Medical Genetics and Genomics:

Kathleen Beal (Director of Public Relations, American College of Medical Genetics and Genomics, Bethesda, MD, USA)

Tel: +1 301 238 4582; E-mail: kbeal@acmg.net

Press contacts:

For media inquiries relating to embargo policy for the journal Genetics in Medicine:

Lisa Boucher (*Nature* London)

Tel: +44 20 7843 4804; E-mail: l.boucher@nature.com

Neda Afsarmanesh (*Nature* New York)

Tel: +1 212 726 9231; E-mail: n.afsarmanesh@us.nature.com

About Nature Publishing Group (NPG)

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.

Focusing on the needs of scientists, *Nature* (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of *Nature* research journals and *Nature Reviews* journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including *Nature News* and *NatureJobs* plus access to *Nature Network* and Nature Education's Scitable.com.

Scientific American is at the heart of NPG's newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, *Scientific American* is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it reaches over 3 million

consumers and scientists. Other titles include *Scientific American Mind* and *Spektrum der Wissenschaft* in Germany.

Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.

Neda Afsarmanesh

Senior Press Officer

Nature Publishing Group

75 Varick St, 9th Floor

New York, NY 10013, USA

t: (212) 726-9231

f: (646) 563-7117

e: n.afsarmanesh@us.nature.com

w: www.nature.com